Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Updates on Mechanism and Management of Gynecological Cancer
share announcement

Updates on Mechanism and Management of Gynecological Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (25 August 2024) | Viewed by 4692

Special Issue Editors

Prof. Dr. Giorgio Valabrega

E-Mail Website
Guest Editor
Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy
Interests: Immunotherapy in endometrial and cervical cancer; targeted therapies in ovarian cancer; clinical trials in gynaecological cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Margherita Turinetto

E-Mail Website
Guest Editor
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
Interests: clinical research; translational research; gynecological cancer

Special Issue Information

Dear Colleagues,

As of late, immunotherapy has been front and center in the development of new strategies for the treatment of endometrial cancer (EC). Up to 30% of new diagnoses and 13 to 30% of recurrent EC are microsatellite instability-high (MSI-H), a clinical setting wherein studies have shown great results, with Dostarlimab showing response rates of 42% (1), Pembrolizumab of 57% (2), and PD-L1 inhibitors such as Durvalumab of 43% (3). In microsatellite-stable (MSS) EC, immune checkpoint inhibitors (ICI) have shown more modest but still present activity, making them worthy of further research. The final efficacy analyses of Pembrolizumab-Lenvatinib in the Keynote 158 trial granted FDA approval of this combination therapy in relapsed MSS EC after progression to first-line chemotherapy. Furthermore, trials featuring ICI in both neoadjuvant and adjuvant settings are ongoing.

Although these developments have been extremely encouraging, a deeper understanding of the molecular and immunological drivers of response and resistance will be critical to optimize the use of ICI in EC, as well as expanding to other immunotherapeutic approaches.

In conclusion, this Special Issue welcomes articles that illustrate the mechanisms behind response and resistance to immunotherapy in EC, possible predictive clinical and molecular markers, and novel approaches to immunotherapy such as CAR-T cell therapy and vaccines.

Prof. Dr. Giorgio Valabrega
Dr. Margherita Turinetto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • endometrial cancer
  • checkpoint inhibitors
  • resistance mechanisms
  • predictive biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 1935 KiB  
Article
Salivary Transmembrane Mucins of the MUC1 Family (CA 15-3, CA 27.29, MCA) in Breast Cancer: The Effect of Human Epidermal Growth Factor Receptor 2 (HER2)
by Elena I. Dyachenko and Lyudmila V. Bel’skaya
Cancers 2024, 16(20), 3461; https://doi.org/10.3390/cancers16203461 - 12 Oct 2024
Viewed by 1071
Abstract
The MUC1 family of transmembrane glycoproteins (CA 15-3, CA 27.29, MCA) is aberrantly expressed among patients with breast cancer. Objectives: to measure the level of degradation products of MUC1, including CA 15-3, CA 27.29, and MCA, in the saliva of breast cancer [...] Read more.
The MUC1 family of transmembrane glycoproteins (CA 15-3, CA 27.29, MCA) is aberrantly expressed among patients with breast cancer. Objectives: to measure the level of degradation products of MUC1, including CA 15-3, CA 27.29, and MCA, in the saliva of breast cancer patients and to describe the biochemical processes that influence their expression and the regulation of their biological functions. Methods: The case–control study included three groups (breast cancer, fibroadenomas, and healthy controls). All study participants provided saliva samples strictly before starting treatment. The levels of MUC1, including CA 15-3, CA 27.29, and MCA, free progesterone and estradiol, cytokines (MCP-1, VEGF, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18), and amino acids (Asp, Gln, Gly, His, Leu + Ile, Orn, Phe, Pro, Tyr) were determined. Results: It was shown that the levels of the MUC1 family in the saliva of patients with HER2-positive breast cancer were significantly lower compared to the control group. The level of pro-inflammatory cytokines and the level of free estradiol affected the expression of MUC1. We obtained a reliable relationship between the aggressive nature of tumor growth, an increased level of pro-inflammatory cytokines, a low level of free estradiol, and the suppressed expression of salivary MUC1. Conclusions: Among patients with aggressive breast cancer, a high level of pro-inflammatory cytokines, and a low level of free estradiol, there was an inhibition of the expression of pathologically unchanged glycoprotein MUC1 in saliva. Full article
(This article belongs to the Special Issue Updates on Mechanism and Management of Gynecological Cancer)
►▼ Show Figures

Figure 1

18 pages, 36387 KiB  
Article
MicroRNA Landscape in Endometrial Carcinomas in an Asian population: Unraveling Subtype-Specific Signatures
by Gideon Ze Lin Tan, Sai Mun Leong, Yu Jin, Chik Hong Kuick, Jeremy Joon Keat Chee, San Zeng Low, Ling-Wen Ding, He Cheng, Diana Lim and Susan Swee-Shan Hue
Cancers 2023, 15(21), 5260; https://doi.org/10.3390/cancers15215260 - 2 Nov 2023
Viewed by 1577
Abstract
MicroRNAs (MiRNAs) are small, non-coding RNA molecules that function in RNA silencing and post-transcriptional regulation of gene expression. We analyzed the differential expression of miRNAs in 119 endometrial carcinomas, measuring their expression in histological subtypes, molecular subtypes, and tumors with CTNNB1 mutations. Tumors [...] Read more.
MicroRNAs (MiRNAs) are small, non-coding RNA molecules that function in RNA silencing and post-transcriptional regulation of gene expression. We analyzed the differential expression of miRNAs in 119 endometrial carcinomas, measuring their expression in histological subtypes, molecular subtypes, and tumors with CTNNB1 mutations. Tumors were subdivided into histological and molecular subtypes as defined by The Cancer Genome Atlas. The expression levels of 352 miRNAs were quantified using the PanoramiR panel. Mir-449a, mir-449b-5p, and mir-449c-5p were the top three miRNAs showing increased expression in both endometrioid and de-differentiated carcinomas but were not significantly increased in serous and clear cell carcinomas. The miRNAs with the most increased expression in serous and clear cell carcinomas were miR-9-3p and miR-375, respectively. We also identified 62 differentially expressed miRNAs among different molecular subtypes. Using sequential forward selection, we built subtype classification models for some molecular subtypes of endometrial carcinoma, comprising 5 miRNAs for MMR-deficient tumors, 10 miRNAs for p53-mutated tumors, and 3 miRNAs for CTNNB1-mutated tumors, with areas under curves of 0.75, 0.85, and 0.78, respectively. Our findings confirm the differential expression of miRNAs between various endometrial carcinoma subtypes and may have implications for the development of diagnostic and prognostic tools. Full article
(This article belongs to the Special Issue Updates on Mechanism and Management of Gynecological Cancer)
►▼ Show Figures

Graphical abstract

14 pages, 67341 KiB  
Article
Vascular and Urinary Tract Anatomic Variants Relevant to Para-Aortic Lymphadenectomy in Women with Gynecological Cancers
by Nina Kovačević, Marko Hočevar, Gregor Vivod and Sebastjan Merlo
Cancers 2023, 15(20), 4959; https://doi.org/10.3390/cancers15204959 - 12 Oct 2023
Cited by 2 | Viewed by 1274
Abstract
Background: Para-aortic lymphadenectomy is an essential part of gynecologic oncologic surgical treatment. The surgeon should be aware of the complex usual anatomy and its common variants. Methods: Between January 2021 and May 2023, 58 women underwent para-aortic lymphadenectomy for gynecologic malignancies. Results: Vascular [...] Read more.
Background: Para-aortic lymphadenectomy is an essential part of gynecologic oncologic surgical treatment. The surgeon should be aware of the complex usual anatomy and its common variants. Methods: Between January 2021 and May 2023, 58 women underwent para-aortic lymphadenectomy for gynecologic malignancies. Results: Vascular and urinary tract anatomic variants were retrospectively reviewed from the prospective institutional database and results were compared with preoperative contrast-enhanced abdominal CT. Of these 58 women, 47 women had no vascular or urinary tract variants. One woman had a double inferior vena cava, two patients were found to have a retro-aortic left renal vein, four had accessory renal arteries, two had a double left ureter, one had a ptotic kidney in the iliac fossa, and one patient had bilateral kidney malrotation. Anatomic variants in the preoperative CT were described by a radiologist in only two patients, and additional vascular and urinary tract variants were found incidentally at the time of surgery. Conclusions: Acknowledgment of vascular and urinary tract variants is helpful for the surgeon to establish an appropriate surgical plan and to avoid iatrogenic surgical trauma. Full article
(This article belongs to the Special Issue Updates on Mechanism and Management of Gynecological Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop